CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. - Wikidata - awgldk - TriplyDB

CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy.

CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy.

http://www.wikidata.org/entity/Q39153898

about

CD133: to be or not to be, is this the real question?Application of optically-induced-dielectrophoresis in microfluidic system for purification of circulating tumour cells for gene expression analysis- Cancer cell line model Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion CD133, Selectively Targeting the Root of Cancer Identification of Personalized Chemoresistance Genes in Subtypes of Basal-Like Breast Cancer Based on Functional Differences Using Pathway Analysis MRI Virtual Biopsy and Treatment of Brain Metastatic Tumors with Targeted Nanobioconjugates: Nanoclinic in the Brain Circulating Tumor Cells: From Theory to Nanotechnology-Based Detection.The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical Resection Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis.Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer.Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.Efficient detection of human circulating tumor cells without significant production of false-positive cells by a novel conditionally replicating adenovirus.Circulating Tumour Cells as an Independent Prognostic Factor in Patients with Advanced Oesophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy.Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma.Advanced technologies for studying circulating tumor cells at the protein level.Cancer stem cells: are they responsible for treatment failure?Circulating tumor cells in breast cancer beyond the genotype of primary tumor for tailored therapy.Epigenetic Regulation of CD133 in Gastrointestinal Stromal Tumors.Blocking NOTCH Pathway can Enhance the Effect of EGFR Inhibitor through Targeting CD133+ Endometrial Cancer Cells.Canine cell line, IPC-366, as a good model for the study of inflammatory breast cancer.Isolation and characterization of circulating tumor cells from human gastric cancer patients.Circulating tumor cells in breast cancer: applications in personalized medicine.Circulating Tumor Cells as Cancer Biomarkers in the Clinic.Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer".Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer.Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133+/EpCAM+ phenotype: a promising target for preventing progression of TNBC.Prognostic value of circulating CD133(+) cells in patients with gastric cancer.Differential CD133 expression distinguishes malignant from benign papillary lesions of the breast.Circulating Tumor Cells: Markers and Methodologies for Enrichment and Detection.Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy.The roles of serum PDCD5 in circulating CD133 positive cells of the patients with gastric cancer.The evolving concepts of cancer stem cells in head and neck squamous cell carcinoma.Ceramide Metabolism Balance, a Multifaceted Factor in Critical Steps of Breast Cancer Development

P2860

Q24615405-A66AD5A2-A13A-41F4-9B64-4FADBE727083 Q27349679-5DECA931-F0EF-4BB1-AAFB-BAE5FCCF1D85 Q28066285-ED19BD50-7356-4CCB-B738-496B402E26FF Q28066353-2AD735A9-8DC9-41C8-A0EF-465A52322F13 Q28545978-73ADC160-7DCB-4FC4-8B29-CC2A46F8D676 Q29248327-BEDCF64B-2FAD-448B-AA6A-438005F6D54C Q30363234-A0E87260-27A6-48C8-ABF7-7CBE76252CA2 Q30978083-6FEC2CC3-1B6C-4DB8-8CD7-A710790DC088 Q35935317-54B2E33F-2DC4-4CAF-898F-7253076243DD Q36292530-C87AF39C-92C8-4C04-90D3-0D823B7EFEC8 Q36441530-8262F011-9551-447D-8917-D544DACA7D26 Q36564710-4DB1E36B-9CAC-4C91-B616-B6BC21133A3E Q36640843-9E4CCC1C-D769-4CC2-BB16-08869380DC5A Q37181546-4A367C44-45AD-44CE-AACD-815BADBF6E2A Q37708834-DE94D22D-0BEE-4580-AEB0-C4326F79BF38 Q38160932-FE955B1E-B0FE-44CD-A740-672BCB69B2F3 Q38268164-869063FA-7B53-4DEA-8796-D9F7B78EFFF5 Q38547813-DACC7D9F-EF61-4004-A9A7-67C0B1739466 Q38708102-97640556-640A-434A-8B36-B01D7AB666AD Q38735642-B99566C8-62E3-4628-B5FF-10D2A7007047 Q38773135-61BE4609-56D7-4F4D-9A44-DFF207F89106 Q38946865-CFDCEEE9-8792-4B9F-B067-E487D446D4C1 Q38985771-BD320736-BD2A-45B6-8A10-2444BCE52FBA Q39339875-E735F2B8-6788-41D2-A1AA-D5069679EF36 Q39900695-6BE0E3D7-E9EE-48C0-87E8-1F0994EC5558 Q41182171-E250A4C1-72C8-472E-A178-37CE27AD1B11 Q41611344-DA0D975D-375D-4D28-9D33-60D5699FE7A7 Q43484960-7CABBE08-8C04-45DA-9680-FF818CE73085 Q44473846-BFF5E60E-448C-4734-8677-F64F5DC7A88D Q50199981-00FB1B54-8BA4-4786-9CC5-2225FD2F7BC6 Q50720110-CD58452E-AE66-4CFF-8EBE-6CB05D67A565 Q52994134-0A502B37-1716-4BBA-AA43-6E5438899116 Q55617784-DC042C4D-4387-49C4-BA58-4223071B3C9D Q57107532-E892C797-705C-4D84-AB7C-3A8A5C095BFE

P2860

CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy.

http://www.wikidata.org/entity/Q39153898

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

CD133 expression in circulatin ...... in resistance to chemotherapy.

@en

CD133 expression in circulatin ...... in resistance to chemotherapy.

@nl

type

label

CD133 expression in circulatin ...... in resistance to chemotherapy.

@en

CD133 expression in circulatin ...... in resistance to chemotherapy.

@nl

prefLabel

CD133 expression in circulatin ...... in resistance to chemotherapy.

@en

CD133 expression in circulatin ...... in resistance to chemotherapy.

@nl

P1433

Q39153898-8D8D19EC-1A37-4980-84A5-D38EE16FA68D

P1476

Q39153898-20CE9065-4BC6-4D0A-BC19-ECA78E9D873A

P2093

Q39153898-15C75A37-C54E-4D25-A862-79595B5245A1

Q39153898-208CE927-713C-44E3-84BA-C5E30E454771

Q39153898-5D617F62-E1FE-456D-925C-66D38D48802D

Q39153898-5F3C61DA-1E5F-4978-8166-DAD71F7D14AA

Q39153898-6BE8CD19-54F2-4F79-9F1E-240A142B759B

Q39153898-8B663B75-7D98-4EC1-BFC4-6FCC6726464D

Q39153898-94AFFD9E-E7F6-4E6A-B5EE-CCCDF3D443EA

Q39153898-AA9909F2-978C-44E2-83E7-150A095FF952

Q39153898-AC532EF6-A4C0-4E47-ACA8-C1062F634E88

Q39153898-CF4F92D0-0791-4B2E-A61C-BFC5EC8BC9AE

P2860

Q39153898-022F93F7-F8B4-4E1A-8810-8F25500D955F

Q39153898-06ECED96-5BEF-488F-972A-CB5D241A3267

Q39153898-07695C43-E437-4481-AFFC-7EBAFD3FEBE8

Q39153898-0B68EFF3-9892-46EB-BEF3-5D80DCBDD61D

Q39153898-0F806E5B-B06B-40EB-A166-EA2DD2DDC9C5

Q39153898-1AE43266-BDB5-4328-A56D-9A2B3CD8FA94

Q39153898-2169547A-F6F7-4E0B-894E-81CF69AC8C6E

Q39153898-39C5FD67-75CC-4D6D-B510-D31B83C9191E

Q39153898-4F0ADE5E-2A91-478A-B64E-488F65411EBC

Q39153898-4F7B29C5-DFE4-4D25-8267-C70DC09F1D73

P304

Q39153898-B5EE79DF-1A6B-4EB7-8913-DFA9A85A10B0

P31

Q39153898-69672E1C-A925-4675-BD90-750AA941FAB0

P356

Q39153898-0862F20E-613D-4B84-BEBB-B27A9F35DAF9

P433

Q39153898-C220B406-36F0-4D2F-996D-4D47EDB46C72

P478

Q39153898-B6AA69BA-A0A2-4384-B1EC-2449665C7543

P50

Q39153898-869FAD25-ADC9-4C50-A434-211BF1518337

P577

Q39153898-83D3AF60-3DD4-4437-948D-537EC3792BB5

P5875

Q39153898-4791A5A0-0670-4E27-94EE-0E686EDABFB7

P698

Q39153898-FE5BAF28-3DB8-4616-A8F6-B86EEC6A7B4B

P921

Q39153898-715EF87E-5D06-4738-968B-8DD91CB1D208

P356

P1433

International Journal of Cancer

P1476

CD133 expression in circulatin ...... in resistance to chemotherapy.

@en

P2093

Ana Fernández

http://www.w3.org/2001/XMLSchema#string

F Gabriel Ortega

http://www.w3.org/2001/XMLSchema#string

Francesc Solé

http://www.w3.org/2001/XMLSchema#string

J Luis García-Puche

http://www.w3.org/2001/XMLSchema#string

Josep M Corominas

http://www.w3.org/2001/XMLSchema#string

M Jose Serrano

http://www.w3.org/2001/XMLSchema#string

Maria Rodríguez-Rivera

http://www.w3.org/2001/XMLSchema#string

Marta Macià

http://www.w3.org/2001/XMLSchema#string

Marta Salido

http://www.w3.org/2001/XMLSchema#string

Miguel Delgado-Rodríguez

http://www.w3.org/2001/XMLSchema#string

P2860

The epithelial-mesenchymal transition generates cells with properties of stem cells

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome

IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland

Prospective identification of tumorigenic breast cancer cells

Identification and expansion of human colon-cancer-initiating cells

Identification of selective inhibitors of cancer stem cells by high-throughput screening

Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content

CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer

Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

P304

2398-2407

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.28263

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

133

http://www.w3.org/2001/XMLSchema#string

P50

José Antonio Lorente

P577

2013-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236675685

http://www.w3.org/2001/XMLSchema#string

P698

23661576

http://www.w3.org/2001/XMLSchema#string

P921